Who decides when vaccine studies are done? Internal documents show Fauci plays a key role 3 ways a Biden White House could impact healthcare Lab survey illustrates testing delays spreading to non-COVID diagnostic areas Global healthcare funding hit a record in Q3. Here's how much digital health companies raised Biopharma roundup: J&J's trial pause still 'unexplained' Evotec nabs Gates Foundation cash for low-income country COVID-19 antibody work LabCorp launches COVID-19 antibody test for measuring vaccine effectiveness KFF: ACA premiums to rise by 1% in 2021 amid COVID-19 uncertainty Aligos, Tarsus bank $238M as biotech IPO party continues Antimicrobial posters: In-office content provider gives ad boards a COVID-19-safe refresh Featured Story | By Isaac Arnsdorf, Caroline Chen and Ryan Gabrielson, ProPublica Dr. Anthony Fauci will see data from government-funded vaccine trials before the FDA does. One caveat: Pfizer’s study, which is ahead of the others, isn’t included in his purview. read more |
| |
|---|
|
| | Webinar: The Power of Virtual Health Assessments during COVID Tuesday, October 27 | 11am ET / 8am PT COVID-19 has forced us to rethink how we effectively support members, and manage quality improvement and risk adjustment initiatives. This webinar provides a look at how Virtual Health Assessments improve healthcare outcomes for members, providers, and payers. Explore how Advantmed’s telehealth solution supports quality improvement and risk adjustment. Register Today. |
Top Stories By Robert King How would a Joe Biden White House impact the healthcare industry? Here's what several experts had to say about what to watch as the election nears. read more By Conor Hale Despite widespread increases in the production of COVID-19 test kits this year, about three-out-of-four surveyed U.S. laboratories still report that they do not have enough supplies to meet the pandemic’s demand. read more By Heather Landi Global healthcare funding soared in the third quarter, hitting a new record of $21.8 billion across 1,539 deals. Here are the sectors drawing the most interest from investors. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner Anthony Fauci will oversee data on many U.S. shot trials, but not Pfizer's, ProPublica reports. J&J's lack of transparency on its clinical hold drew fire from health experts. The National Governor's Association is demanding to know exactly how a shot rollout will work. And a price tag for Sinovac's shot has emerged. read more By Ben Adams German biotech-CRO hybrid Evotec has been handed a lump sum to help develop the next generation of antibodies to treat patients sick with COVID-19. read more By Conor Hale LabCorp has launched a new COVID-19 antibody test designed to gauge the strength of a person’s immune response to the virus, for use in clinical trials of potential vaccines and therapies. read more By Robert King Premiums on the Affordable Care Act's exchanges are expected to rise slightly next year, but insurers are still struggling to figure out how COVID-19 will impact healthcare costs, report finds. read more By Amirah Al Idrus Let’s add two more to the list—a pair of clinical-stage biotechs collectively raised more than $200 million in their Nasdaq debuts. Hepatitis B and COVID-19-focused Aligos Therapeutics raised $150 million, while eye disease player Tarsus Pharmaceuticals reeled in $88 million. read more By Beth Snyder Bulik While many healthcare professionals enjoy the camaraderie of office lunchrooms, they probably don’t want extra contagions with their sandwiches—especially during the COVID-19 pandemic. So Physician’s Weekly, the veteran editorial and pharma advertising newsletter-like wallboard provider, decided to take an extra step to make sure its posters were safe. read more |
